Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs offers a comprehensive In Vivo CAR-T Development Service powered by IVT self-amplifying RNA (saRNA) technology. Our platform enables rapid and efficient generation of functional CAR-T cells directly inside the body through advanced saRNA engineering, optimized nanoparticle delivery systems, and precise in vivo expression control. We support every stage of development, including saRNA design, LNP formulation, targeting ligand integration, in vivo induction studies, and performance evaluation, to help clients achieve robust CAR expression, enhanced T-cell expansion, and strong anti-tumor activity. This solution provides a scalable and streamlined path toward next-generation in vivo CAR-T therapeutics.
IVT saRNA enables high-level CAR expression through self-amplifying mechanisms, while targeted delivery systems support selective in vivo programming of T cells. Published research highlights its efficiency, lower dosing requirements, and flexible engineering potential.
Fig.1 The replication cycle of saRNA within cells.1
Creative Biolabs provides a specialized platform for generating functional CAR-T cells directly in vivo using IVT saRNA constructs and targeted delivery formulations. This service enables rapid CAR expression, reduced manufacturing burden, and flexible design options tailored to diverse therapeutic targets. Clients can expect customized saRNA engineering, targeted nanoparticle delivery strategies, immunogenicity minimization solutions, and preclinical-ready evaluation packages. Each project is supported by extensive experience in RNA engineering, immune-cell targeting, and in vivo functional assessment.
Discover How We Can Help - Request a Consultation.
| Core saRNA-CAR Construct Development | saRNA Delivery System |
|---|---|
|
|
| Evaluation & Translational Support | |
|
|
Required Starting Materials:
Key Steps Involved:
Creative Biolabs provides in vivo CAR-T engineering using IVT mRNA to enable rapid, transient, and non-viral CAR expression. This platform supports safer modulation of T-cell activity, flexible dosing control, and efficient antitumor responses without the complexity of ex vivo manufacturing.
Creative Biolabs develops in vivo CAR-T solutions using circular RNA, offering enhanced molecular stability, prolonged CAR expression, and reduced immunogenicity. This approach supports durable T-cell functionality and efficient tumor targeting while eliminating the need for viral vectors or ex vivo manipulation.
Creative Biolabs leverages LNP-DNA technology to achieve stable, non-viral CAR insertion directly in vivo. This strategy enables scalable production, precise gene delivery, and robust CAR-T generation within the body, facilitating sustained antitumor efficacy and streamlined therapeutic development.
What advantages does saRNA offer over conventional mRNA for in vivo CAR-T generation?
saRNA supports prolonged expression with lower doses. It is well suited for systemic or local delivery and can enhance overall CAR induction.
Can this platform target specific T-cell subsets?
Yes. Ligand-modified delivery systems can preferentially target CD4+, CD8+, or mixed T-cell populations. Customized targeting strategies are available upon request.
What preclinical models are supported?
We support immunocompetent, humanized, and xenograft models, depending on the client's research needs. Inquiry is encouraged to determine the optimal model for your program.
How do you control innate immune activation caused by saRNA?
We apply optimized UTRs, sequence engineering, and advanced purification to reduce dsRNA contaminants. Additional mitigation strategies can be integrated based on project goals.
Creative Biolabs provides an end-to-end saRNA-based in vivo CAR-T development solution backed by advanced RNA engineering capabilities and extensive experience in targeted delivery systems. Published Data support the high expression efficiency and prolonged activity of optimized saRNA constructs, and our development team applies these principles to generate robust, repeatable results for preclinical applications. Experience the Creative Biolabs Advantage – Get a Quote Today.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
